Somewhat Positive Press Coverage Somewhat Unlikely to Impact Unity Biotechnology (UBX) Share Price
News stories about Unity Biotechnology (NASDAQ:UBX) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Unity Biotechnology earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.3060422427911 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
A number of analysts recently commented on the company. Morgan Stanley initiated coverage on Unity Biotechnology in a research report on Tuesday, May 29th. They set an “overweight” rating and a $25.00 price objective for the company. Goldman Sachs Group initiated coverage on Unity Biotechnology in a research report on Tuesday, May 29th. They issued a “neutral” rating and a $17.00 price target for the company. Finally, Citigroup initiated coverage on Unity Biotechnology in a research report on Tuesday, May 29th. They issued a “buy” rating and a $32.00 price target for the company.
UBX traded up $0.37 during midday trading on Wednesday, reaching $15.20. The company had a trading volume of 3,149 shares, compared to its average volume of 119,360. Unity Biotechnology has a 1 year low of $12.75 and a 1 year high of $20.48.
Unity Biotechnology, Inc, a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases.
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.